Palvella Therapeutics holder plans $58.9K sale

Stockholder Christopher Kiritsy filed a Rule 144 notice to sell 375 PVLA common shares valued at $58,875 following a stock option exercise.

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS, INC. (PVLA) is the issuer for a proposed sale of common stock reported under Rule 144 by stockholder Christopher Kiritsy. The notice covers 375 shares of common stock, with an indicated value of $58,875.00, to be sold through Morgan Stanley Smith Barney LLC on or after September 2, 2026.

The shares are to be issued in connection with a stock option exercise, with the issuer listed as the party for the option exercise and cash as the form of payment. The securities are listed as trading on NASDAQ.

Key Figures

Shares proposed to be sold: 375 shares Indicated value of securities: $58,875.00 Proposed sale date: September 2, 2026 +2 more

5 metrics

Shares proposed to be sold 375 shares Common stock reported for sale under Rule 144

Indicated value of securities $58,875.00 Value associated with 375 shares of common stock

Proposed sale date September 2, 2026 Date listed for the securities transaction

Security type Common stock Palvella Therapeutics, Inc. equity security to be sold

Trading market NASDAQ Market listed for the common stock

Key Terms

Rule 144, Stock Option Exercise, Common

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 09/02/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Common financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

What is being reported in this Form 144 related to PVLA?

The filing reports a proposed sale under Rule 144 of 375 shares of Palvella Therapeutics, Inc. common stock by stockholder Christopher Kiritsy, with an indicated value of $58,875.00, to be sold through Morgan Stanley Smith Barney LLC.

Who is selling PVLA shares according to this Form 144?

The notice lists Christopher Kiritsy as the person for whose account the Palvella Therapeutics, Inc. common stock is to be sold, with information provided in accordance with Rule 144 aggregation requirements.

How many PVLA shares are covered and what is their value?

The Form 144 covers 375 shares of Palvella Therapeutics, Inc. common stock with an indicated total value of $58,875.00 in the securities information section.

What is the nature of the PVLA transaction in this Form 144?

The securities to be sold are tied to a stock option exercise, with the issuer identified as the party in the exercise and cash as the form of payment, followed by a proposed sale of the resulting shares.

When is the proposed sale of PVLA shares expected to occur?

The Form 144 lists September 2, 2026 as the relevant date in both the securities information section and the securities-to-be-sold section for the proposed transaction.

Through which broker will the PVLA shares be sold?

The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, as the broker handling the proposed sale of Palvella Therapeutics, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:10 PM Accepted by SEC EDGAR 09/02/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001261156
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PALVELLA THERAPEUTICS, INC.
SEC File Number	001-37471
Address of Issuer	353 W. LANCASTER AVENUE SUITE 200 WAYNE PENNSYLVANIA 19087
Phone	(484) 253-1461
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER KIRITSY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	375	58875.00	14408407	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Stock Option Exercise	Issuer			375	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Kiristsy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)